Novavax Inc (NVAX)
7.70
-0.07
(-0.90%)
USD |
NASDAQ |
Nov 14, 12:05
Novavax Research and Development Expense (Quarterly): 106.95M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 106.95M |
| March 31, 2024 | 92.68M |
| December 31, 2023 | 164.70M |
| September 30, 2023 | 106.23M |
| June 30, 2023 | 219.48M |
| March 31, 2023 | 247.10M |
| December 31, 2022 | 257.85M |
| September 30, 2022 | 304.30M |
| June 30, 2022 | 289.65M |
| March 31, 2022 | 383.48M |
| December 31, 2021 | 962.96M |
| September 30, 2021 | 408.20M |
| June 30, 2021 | 570.68M |
| March 31, 2021 | 592.67M |
| December 31, 2020 | 401.20M |
| September 30, 2020 | 294.09M |
| June 30, 2020 | 34.85M |
| March 31, 2020 | 16.90M |
| December 31, 2019 | 29.34M |
| September 30, 2019 | 18.61M |
| June 30, 2019 | 30.42M |
| March 31, 2019 | 35.47M |
| December 31, 2018 | 43.42M |
| September 30, 2018 | 41.33M |
| June 30, 2018 | 44.54M |
| Date | Value |
|---|---|
| March 31, 2018 | 44.51M |
| December 31, 2017 | 49.66M |
| September 30, 2017 | 41.86M |
| June 30, 2017 | 39.26M |
| March 31, 2017 | 37.65M |
| December 31, 2016 | 51.10M |
| September 30, 2016 | 52.98M |
| June 30, 2016 | 64.90M |
| March 31, 2016 | 68.95M |
| December 31, 2015 | 75.90M |
| September 30, 2015 | 30.66M |
| June 30, 2015 | 27.73M |
| March 31, 2015 | 28.35M |
| December 31, 2014 | 45.48M |
| September 30, 2014 | 19.22M |
| June 30, 2014 | 15.20M |
| March 31, 2014 | 14.52M |
| December 31, 2013 | 24.54M |
| September 30, 2013 | 13.95M |
| June 30, 2013 | 10.78M |
| March 31, 2013 | 9.256M |
| December 31, 2012 | 9.637M |
| September 30, 2012 | 6.642M |
| June 30, 2012 | 5.371M |
| March 31, 2012 | 5.338M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
16.90M
Minimum
Mar 2020
962.96M
Maximum
Dec 2021
288.59M
Average
257.85M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc | 2.598B |
| Moderna Inc | 1.137B |
| Baxter International Inc | 129.00M |
| Inovio Pharmaceuticals Inc | 23.09M |
| AIM ImmunoTech Inc | 1.145M |